A pooled analysis of real-world data from over 2,000 patients with epilepsy has shown that Eisai and Bial’s Zebinix is safe and effective when switching from previous treatment with carbamazepine or oxcarbazepine.
The Euro-Esli study pooled data from 14 European clinical practice studies including 2,058 patients aged 14-88 years old with partial-onset seizures (POS), with or without secondary generalisation, to examine the real world use of Zebinix (eslicarbazepine) as monotherapy, as well as adjunctive therapy, in clinical practice.
After 12 months of treatment with Zebinix, responder and seizure freedom rates for patients transitioning from carbamazepine due to lack of efficacy (n=163) were 70 percent and 30.9 percent, respectively.
Corresponding values for those transitioning from oxcarbazepine due to lack of efficacy (n=90) were 57.1 percent and 25.0 percent, respectively, while among patients who switch from carbamazepine and oxcarbazepine to Zibinix due to lack of efficacy, 11.6 percent and 10.5 percent discontinued treatment due to lack of efficacy, respectively.
The firms say the data show the drug is effective and well-tolerated as a monotherapy in patients transitioning from carbamazepine or oxcarbazepine in clinical practice.
Epilepsy is one of the most common neurological conditions in the world, affecting approximately fifty million people in Europe.
Zebinix was first approved in Europe in 2009 as adjunctive therapy in adults, adolescents and children aged above six years, with partial-onset seizures with or without secondary generalization, and earlier this year as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy.